Safety and Efficacy in Parous Women of a 52-mg Levonorgestrel-medicated Intrauterine Device: a 7-year Randomized Comparative Study with the TCu380A

Overview

Journal Contraception

Publisher Elsevier

Specialty Reproductive Medicine

Date 2016 Feb 27

PMID 26916172

Citations 33

Authors

Patrick Rowe

Tim Farley

Alexandre Peregoudov

Gilda Piaggio

Simone Boccard

Sihem Landoulsi

Olav Meirik

Affiliations

Soon will be listed here.

Abstract

Objectives: To compare rates of unintended pregnancy, method continuation and reasons for removal among women using the 52-mg levonorgestrel (daily release 20 microg) intrauterine device (LNG-IUD) or the copper T 380 A IUD (TCu380A).

Study Design: This was an open-label 7-year randomized controlled trial in 20 centres, 11 of which in China. Data on 1884 women with interval insertion of the LNG-IUD and 1871 of the TCu380A were analysed using life tables with 30-day intervals and Cox proportional hazards models.

Results: The cumulative 7-year pregnancy rate of the LNG-IUD was 0.5 (standard error 0.2) per 100, significantly lower than 2.5 (0.4) per 100 of the TCu380A, cumulative method discontinuation rates at 7 years were 70.6 (1.2) and 40.8 (1.3) per 100, respectively. Dominant reasons for discontinuing the LNG-IUD were amenorrhea (26.1 [1.3] per 100) and reduced bleeding (12.5 [1.1] per 100), particularly in Chinese women and, for the TCu380A, increased bleeding (9.9 [0.9] per 100), especially among non-Chinese women. Removal rates for pain were similar for the two intrauterine devices (IUDs). Cumulative rates of removal for symptoms compatible with hormonal side effects were 5.7 (0.7) and 0.4 (0.2) per 100 for the LNG-IUD and TCu380A, respectively, and cumulative losses to follow-up at 7 years were 26.0 (1.4) and 36.9 (1.3) per 100, respectively.

Conclusion: The LNG-IUD and the TCu380A have very high contraceptive efficacy, with the LNG-IUD significantly higher than the TCu380A. Overall rates of IUD removals were higher among LNG-IUD users than TCu380A users. Removals for amenorrhea appeared culturally associated.

Implications: The 52-mg LNG-IUD and the TCu380A have very high contraceptive efficacy through 7 years. As an IUD, the unique side effects of the LNG-IUD are reduced bleeding, amenorrhea and symptoms compatible with hormonal contraceptives.

Citing Articles

Contraception with levonorgestrel-releasing intrauterine system versus copper intrauterine device: a meta-analysis of randomized controlled trials.

Liu P, Meng J, Xiong Y, Wu Y, Xiao Y, Gao S EClinicalMedicine. 2024; 78:102926.

PMID: 39610901 PMC: 11602564. DOI: 10.1016/j.eclinm.2024.102926.

Risk factors of uterine perforation when using contraceptive intrauterine devices.

Tabatabaei F, Hosseini S, Hakimi P, Vejdani R, Khademi B BMC Womens Health. 2024; 24(1):538.

PMID: 39334324 PMC: 11428400. DOI: 10.1186/s12905-024-03298-3.

S2k-Guideline Non-hormonal Contraception, Part 2: Intrauterine Devices and Sterilization: Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015 - 095, January 2024).

Bottcher B, Beckermann M, Berger B, Cremers J, DCosta E, Frank-Herrmann P Geburtshilfe Frauenheilkd. 2024; 84(8):715-736.

PMID: 39114382 PMC: 11303009. DOI: 10.1055/a-2317-8993.

S2k-Guideline Non-hormonal Contraception, Part 1: Natural Family Planning, Lactational Amenorrhea, Barrier Methods, Coitus Interruptus: Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015 - 095, January 2024).

Bottcher B, Beckermann M, Berger B, Cremers J, DCosta E, Frank-Herrmann P Geburtshilfe Frauenheilkd. 2024; 84(8):697-714.

PMID: 39114381 PMC: 11303010. DOI: 10.1055/a-2317-9133.

Trends in Continuation of Long-Acting Reversible Contraception Among Adolescents Receiving Medicaid.

Allison B, Ritter V, Lin F, Flower K, Perry M J Adolesc Health. 2024; 75(3):487-495.

PMID: 38980246 PMC: 11330372. DOI: 10.1016/j.jadohealth.2024.04.029.

References

Backman T, Rauramo I, Huhtala S, Koskenvuo M . Pregnancy during the use of levonorgestrel intrauterine system. Am J Obstet Gynecol. 2004; 190(1):50-4. DOI: 10.1016/j.ajog.2003.07.021. View

Heinemann K, Reed S, Moehner S, Minh T . Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices. Contraception. 2015; 91(4):280-3. DOI: 10.1016/j.contraception.2015.01.011. View

French R, van Vliet H, Cowan F, Mansour D, Morris S, Hughes D . Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy. Cochrane Database Syst Rev. 2004; (3):CD001776. PMC: 8407482. DOI: 10.1002/14651858.CD001776.pub2. View

TIETZE C, Lewit S . Recommended procedures for the statistical evaluation of intrauterine contraception. Stud Fam Plann. 1973; 4(2):35-42. View

LUUKKAINEN T, Allonen H, Haukkamaa M, Lahteenmaki P, Nilsson C, Toivonen J . Five years' experience with levonorgestrel-releasing IUDs. Contraception. 1986; 33(2):139-48. DOI: 10.1016/0010-7824(86)90080-6. View

Andersson K, Odlind V, RYBO G . Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception. 1994; 49(1):56-72. DOI: 10.1016/0010-7824(94)90109-0. View

Sivin I, Stern J, Coutinho E, Mattos C, El mahgoub S, Diaz S . Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS. Contraception. 1991; 44(5):473-80. DOI: 10.1016/0010-7824(91)90149-a. View

Farley T . Life-table methods for contraceptive research. Stat Med. 1986; 5(5):475-89. DOI: 10.1002/sim.4780050512. View

Madden T, McNicholas C, Zhao Q, Secura G, Eisenberg D, Peipert J . Association of age and parity with intrauterine device expulsion. Obstet Gynecol. 2014; 124(4):718-726. PMC: 4172535. DOI: 10.1097/AOG.0000000000000475. View

10.

OBrien P, Kulier R, Helmerhorst F, Usher-Patel M, dArcangues C . Copper-containing, framed intrauterine devices for contraception: a systematic review of randomized controlled trials. Contraception. 2008; 77(5):318-27. DOI: 10.1016/j.contraception.2007.12.011. View

11.

. Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C. Contraception. 1998; 56(6):341-52. View

12.

LUUKKAINEN T, Allonen H, Haukkamaa M, Holma P, PYORALA T, TERHO J . Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study. Contraception. 1987; 36(2):169-79. DOI: 10.1016/0010-7824(87)90012-6. View

13.

Toivonen J, LUUKKAINEN T, Allonen H . Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstet Gynecol. 1991; 77(2):261-4. DOI: 10.1097/00006250-199102000-00019. View

14.

Diedrich J, Madden T, Zhao Q, Peipert J . Long-term utilization and continuation of intrauterine devices. Am J Obstet Gynecol. 2015; 213(6):822.e1-6. PMC: 4679676. DOI: 10.1016/j.ajog.2015.08.077. View

15.

Meirik O, Rowe P, Peregoudov A, Piaggio G, Petzold M . The frameless copper IUD (GyneFix) and the TCu380A IUD: results of an 8-year multicenter randomized comparative trial. Contraception. 2009; 80(2):133-41. DOI: 10.1016/j.contraception.2009.02.006. View

16.

Eisenberg D, Schreiber C, Turok D, Teal S, Westhoff C, Creinin M . Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system. Contraception. 2015; 92(1):10-6. DOI: 10.1016/j.contraception.2015.04.006. View

17.

Hidalgo M, Hidalgo-Regina C, Valeria Bahamondes M, Monteiro I, Petta C, Bahamondes L . Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system. Contraception. 2009; 80(1):84-9. DOI: 10.1016/j.contraception.2009.01.004. View

18.

Sivin I, El mahgoub S, McCarthy T, Mishell Jr D, Shoupe D, Alvarez F . Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study. Contraception. 1990; 42(4):361-78. DOI: 10.1016/0010-7824(90)90046-x. View

19.

Baveja R, Bichille L, Coyaji K, ENGINEER A, Gogoi M, Hazra M . Randomized clinical trial with intrauterine devices (levonorgestrel intrauterine device (LNG), CuT 380Ag, CuT 220C and CuT 200B). A 36-month study. Indian Council of Medical Research Task Force on IUD. Contraception. 1989; 39(1):37-52. DOI: 10.1016/0010-7824(89)90014-0. View

20.

. The TCu380A, TCu220C, multiload 250 and Nova T IUDS at 3,5 and 7 years of use--results from three randomized multicentre trials. World Health Organization. Special Programme of Research, Development and Research Training in Human Reproduction: Task.... Contraception. 1990; 42(2):141-58. View